KN 387271

Drug Profile

KN 387271

Alternative Names: BAY 7271; BAY-387271; KN 38-7271

Latest Information Update: 20 Aug 2015

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Bayer HealthCare
  • Developer KeyNeurotek Pharmaceuticals AG
  • Class Neuroprotectants; Small molecules
  • Mechanism of Action Cannabinoid receptor agonists; Cannabinoid receptor CB1 agonists; Cannabinoid receptor CB2 agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Craniocerebral trauma
  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Brain injuries; Stroke

Most Recent Events

  • 25 May 2011 Phase I development is ongoing in Germany
  • 25 May 2011 Phase II development is ongoing in Europe
  • 16 Dec 2009 Efficacy data from a phase II trial in traumatic brain injury released by KeyNeurotek
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top